Cargando…

Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease

BACKGROUND: Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), although obese patients with NAFLD do not always develop significant fibrosis. The distribution of body fat could predict the risk of NAFLD progression.  AIM: To investigate the role of bioelectrical impedance-estima...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Conde, Marta, Llop, Elba, Fernández Carrillo, Carlos, Tormo, Beatriz, Abad, Javier, Rodriguez, Luis, Perelló, Christie, López Gomez, Marta, Martínez-Porras, José Luis, Fernández Puga, Natalia, Trapero-Marugan, Maria, Fraga, Enrique, Ferre Aracil, Carlos, Calleja Panero, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673970/
https://www.ncbi.nlm.nih.gov/pubmed/33268953
http://dx.doi.org/10.3748/wjg.v26.i42.6658
_version_ 1783611425485225984
author Hernández-Conde, Marta
Llop, Elba
Fernández Carrillo, Carlos
Tormo, Beatriz
Abad, Javier
Rodriguez, Luis
Perelló, Christie
López Gomez, Marta
Martínez-Porras, José Luis
Fernández Puga, Natalia
Trapero-Marugan, Maria
Fraga, Enrique
Ferre Aracil, Carlos
Calleja Panero, José Luis
author_facet Hernández-Conde, Marta
Llop, Elba
Fernández Carrillo, Carlos
Tormo, Beatriz
Abad, Javier
Rodriguez, Luis
Perelló, Christie
López Gomez, Marta
Martínez-Porras, José Luis
Fernández Puga, Natalia
Trapero-Marugan, Maria
Fraga, Enrique
Ferre Aracil, Carlos
Calleja Panero, José Luis
author_sort Hernández-Conde, Marta
collection PubMed
description BACKGROUND: Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), although obese patients with NAFLD do not always develop significant fibrosis. The distribution of body fat could predict the risk of NAFLD progression.  AIM: To investigate the role of bioelectrical impedance-estimated visceral fat (VF) in assessing NAFLD severity. METHODS: In this cross-sectional study, patients with biopsy-proven NAFLD were prospectively included. All patients underwent anthropometric evaluation, blood tests and bioelectrical impedance analysis. RESULTS: Between 2017 and 2020, 119 patients were included [66.4% male, 56 years (SD 10.7), 62.2% obese, 61.3% with metabolic syndrome]. Sixty of them (50.4%) showed significant fibrosis (≥ F2) in liver biopsy. Age, VF and metabolic syndrome were associated with significant fibrosis (61 years vs 52 years, 16.4 vs 13.1, 73.3% vs 49.2%, respectively; P < 0.001 for all). In the multivariate analysis, VF and age were independently associated with significant fibrosis (VF, OR: 1.11, 95%CI: 1.02-1.22, P = 0.02; age, OR: 1.08, 95%CI: 1.03-1.12, P < 0.01). A model including these variables showed and area under the receiver operating characteristic curve (AUROC) of 0.75, which was not inferior to transient elastography or NAFLD fibrosis score AUROCs. We developed a nomogram including age and VF for assessing significant fibrosis in routine practice. CONCLUSION: VF is a surrogate marker of liver fibrosis in patients with NAFLD. Bioelectrical impedance analysis is an inexpensive and simple method that can be combined with age to guide patient referral when other resources may be unavailable.
format Online
Article
Text
id pubmed-7673970
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-76739702020-12-01 Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease Hernández-Conde, Marta Llop, Elba Fernández Carrillo, Carlos Tormo, Beatriz Abad, Javier Rodriguez, Luis Perelló, Christie López Gomez, Marta Martínez-Porras, José Luis Fernández Puga, Natalia Trapero-Marugan, Maria Fraga, Enrique Ferre Aracil, Carlos Calleja Panero, José Luis World J Gastroenterol Observational Study BACKGROUND: Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), although obese patients with NAFLD do not always develop significant fibrosis. The distribution of body fat could predict the risk of NAFLD progression.  AIM: To investigate the role of bioelectrical impedance-estimated visceral fat (VF) in assessing NAFLD severity. METHODS: In this cross-sectional study, patients with biopsy-proven NAFLD were prospectively included. All patients underwent anthropometric evaluation, blood tests and bioelectrical impedance analysis. RESULTS: Between 2017 and 2020, 119 patients were included [66.4% male, 56 years (SD 10.7), 62.2% obese, 61.3% with metabolic syndrome]. Sixty of them (50.4%) showed significant fibrosis (≥ F2) in liver biopsy. Age, VF and metabolic syndrome were associated with significant fibrosis (61 years vs 52 years, 16.4 vs 13.1, 73.3% vs 49.2%, respectively; P < 0.001 for all). In the multivariate analysis, VF and age were independently associated with significant fibrosis (VF, OR: 1.11, 95%CI: 1.02-1.22, P = 0.02; age, OR: 1.08, 95%CI: 1.03-1.12, P < 0.01). A model including these variables showed and area under the receiver operating characteristic curve (AUROC) of 0.75, which was not inferior to transient elastography or NAFLD fibrosis score AUROCs. We developed a nomogram including age and VF for assessing significant fibrosis in routine practice. CONCLUSION: VF is a surrogate marker of liver fibrosis in patients with NAFLD. Bioelectrical impedance analysis is an inexpensive and simple method that can be combined with age to guide patient referral when other resources may be unavailable. Baishideng Publishing Group Inc 2020-11-14 2020-11-14 /pmc/articles/PMC7673970/ /pubmed/33268953 http://dx.doi.org/10.3748/wjg.v26.i42.6658 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Hernández-Conde, Marta
Llop, Elba
Fernández Carrillo, Carlos
Tormo, Beatriz
Abad, Javier
Rodriguez, Luis
Perelló, Christie
López Gomez, Marta
Martínez-Porras, José Luis
Fernández Puga, Natalia
Trapero-Marugan, Maria
Fraga, Enrique
Ferre Aracil, Carlos
Calleja Panero, José Luis
Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
title Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
title_full Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
title_fullStr Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
title_full_unstemmed Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
title_short Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
title_sort estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673970/
https://www.ncbi.nlm.nih.gov/pubmed/33268953
http://dx.doi.org/10.3748/wjg.v26.i42.6658
work_keys_str_mv AT hernandezcondemarta estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT llopelba estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT fernandezcarrillocarlos estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT tormobeatriz estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT abadjavier estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT rodriguezluis estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT perellochristie estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT lopezgomezmarta estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT martinezporrasjoseluis estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT fernandezpuganatalia estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT traperomaruganmaria estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT fragaenrique estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT ferrearacilcarlos estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease
AT callejapanerojoseluis estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease